A Humira Prescription Costs $38,000 A Year Because Our Patent System Is Being Abused
America's seniors deserve better. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - October 28, 2018 Category: Science Source Type: news

New JAK1 Agent Beats Humira in Rheumatoid Arthritis
(MedPage Today) -- Thrombotic events balanced between upadacitinib, adalimumab, and placebo (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 22, 2018 Category: Rheumatology Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates Fresenius Kabi Acknowledges Validity of AbbVie's Intellectual Property ... Biopharmaceuticals, Litigation, Licensing AbbVie, Fresenius Kabi, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2018 Category: Pharmaceuticals Source Type: news

AbbVie settles Humira biosimilar dispute with Fresenius Kabi
U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe
Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of (Source: World Pharma News)
Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world ’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biosimilars set to benefit patients and the NHS
Today marks the European patent expiry for the biologic Adalimumab (Humira), which is prescribed in hospitals for conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Adalimumab (Humira)
Title: Adalimumab (Humira)Category: MedicationsCreated: 10/16/2018 12:00:00 AMLast Editorial Review: 10/16/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS;...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news